Quick Answer
Vivos Therapeutics, Inc. reported Total Assets of $15.28 million for fiscal year 2024.
Vivos Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2024 | $15.28M | +42.4% |
| 2023 | $10.73M | -21.8% |
| 2022 | $13.72M | -59.3% |
| 2021 | $33.69M | +33.0% |
| 2020 | $25.33M | +235.4% |
| 2019 | $7.55M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $25.64M | +67.1% | -1.5% |
| June 30, 2025 | $26.03M | +64.3% | +130.7% |
| March 31, 2025 | $11.28M | -4.4% | -26.2% |
| December 31, 2024 | $15.28M | +42.4% | -0.4% |
| September 30, 2024 | $15.35M | +48.8% | -3.1% |
| June 30, 2024 | $15.84M | +15.2% | +34.2% |
| March 31, 2024 | $11.80M | -31.0% | +10.0% |
| December 31, 2023 | $10.73M | -21.8% | +4.0% |
- Vivos Therapeutics, Inc. showed an increase of +42.4% in Total Assets compared to the prior fiscal year.
- Over the 2019–2024 period, Vivos Therapeutics, Inc.’s total assets has grown by 102.4% (from $7.55 million to $15.28 million).
- The most recent figure is from Vivos Therapeutics, Inc.’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 31, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: